Home / Health / New Bone Cancer Drug Shows Promising Survival Rates
New Bone Cancer Drug Shows Promising Survival Rates
26 Oct
Summary
- Experimental drug ris-rez extended progression-free survival for patients.
- Patients lived a median of 5.5 months without worsening disease.
- Ris-rez showed a 67% reduction in risk of disease progression or death.
An experimental targeted therapy named ris-rez has shown significant promise in treating a hard-to-treat bone cancer, osteosarcoma. In a late-stage study conducted in China, patients receiving ris-rez lived a median of 5.5 months without their disease worsening, compared to 1.4 months for those on chemotherapy. This represents a substantial improvement over existing treatments.
Developed by Hansoh Pharmaceutical and GSK, ris-rez is described as a "guided missile" therapy, delivering potent drugs directly to tumors while sparing healthy tissue. The study involved 122 patients aged 12 and older with relapsed refractory osteosarcoma who had already undergone multiple lines of treatment. The drug demonstrated a 67% reduction in the risk of disease progression or death.
GSK is strategically rebuilding its oncology presence with drugs like ris-rez. The company has licensed this therapy from Hansoh and is accelerating its development across various cancers. This development is part of GSK's broader push into oncology, aiming to expand beyond its current treatment areas.
